Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
10.19
-0.35 (-3.32%)
At close: Oct 23, 2026, 4:00 PM EDT
10.19
0.00 (0.00%)
After-hours: Oct 23, 2026, 7:30 PM EDT
Climb Bio Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Climb Bio stock has a consensus rating of "Strong Buy" and an average price target of $27.57. The average 1-year stock price forecast is 170.56% higher than the current stock price, while the lowest is $18 (+76.64%) and the highest is $40 (+292.54%).
Price Target: $27.57 (+170.56%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Climb Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 14 | 13 | 13 | 13 | 13 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 14 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Deutsche Bank | Deutsche Bank | Buy Initiates $28 | Buy | Initiates | $28 | +174.78% | Oct 20, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $23 | Buy | Maintains | $23 | +125.71% | Oct 13, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $30 | Buy | Reiterates | $30 | +194.41% | Oct 12, 2026 |
| BTIG | BTIG | Buy Maintains $32 | Buy | Maintains | $32 | +214.03% | Oct 2, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 4, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
500.00K
EPS This Year
-0.78
from -0.88
EPS Next Year
-1.00
from -0.78
EPS and Forward PE are based on non-GAAP adjusted numbers.